Ionis Pharmaceuticals (IONS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS)

IONS 71.53

+2.4%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Micawber who wrote (2526)	3/16/1999 12:09:00 PM
From: sds	Read Replies (2) of 4676

Brian, Further thoughts on the Cowen downgrade... I'm not sure if this is old news, but I got my hands on some information regarding the Cowen downgrade. Basically, the analyst cited the slow sales of Vitravene and the absence of near-term catalysts as the reasons for the downgrade. With the Crohn's data not coming out 'til later this year, he believes there really won't be anything out there to move the stock. Fact is, he's probably right, at least to a point. That said, though, there is an unspoken reason he did the downgrade. He is new, and he probably wants to "clear the decks" of any stocks that might have less than rosy pasts for Cowen. Isis is arguably the definitive controversy stock in biotech (you either believe antisense works and love Isis, or you believe antisense won't work and Isis is destined for Chapter 11), so I can't really blame a new guy for washing his hands of it at this point. Also, a "Buy" is still a "Buy" -- its better than a Neutral. sds

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next